Cassiopeia study multiple myeloma
WebOAB-002: Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM) 作者 Andrzej Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefebvre, Shuchita Kaila, Jianming He, Marie-Hélène Lafeuille, Annelore Cortoos, Anil Londhe, Panagiotis Mavros, … Web2296 Peripheral Neuropathy in the Cassiopeia Study Program: Oral and Poster Abstracts Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II …
Cassiopeia study multiple myeloma
Did you know?
Web5 Jun 2024 · In the phase 3 DETERMINATION trial, patients with newly diagnosed multiple myeloma were randomly assigned to treatment with lenalidomide, bortezomib, and dexamethasone with and without an autologous stem cell transplant (ASCT). All patients received lenalidomide maintenance until progression. Web23 Mar 2024 · Multiple myeloma is a hematologic cancer in which clonal plasma-cell proliferation leads to complications and death. 1 Initial treatment for newly diagnosed …
Web28 Sep 2024 · As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown … Web22 Oct 2024 · In the open-label, multicenter, phase 3 CASSIOPEIA study, investigators enrolled 1085 newly diagnosed patients with previously untreated symptomatic multiple …
WebThe primary end point was the rate of MRD negativity at the end of planned treatment up to 8 cycles for the combination therapy using multiparametric flow cytometry for patients … Web31 Mar 2024 · Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes …
Web18 Jun 2024 · Improvement in health-related qualityof life for newly diagnosed multiple myeloma transplant-eligible patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone: CASSIOPEIA study: weiterlesen: PS1379: Mateos MV: Safety and efficacy of once-weekly carfilzomib dosing in frail patients: A subgroup analysis from the …
WebThis initiative is focused on the development of innovative, patient-centric, early phase trials (Phase 1 or 2) which investigate the potential of new treatments or combinations to … hemp lawsWeb8 Apr 2024 · CASSIOPEIA was a randomized, open-label, phase III trial evaluating the inclusion of daratumumab with VTd before and after ASCT for transplant-eligible patients … hemp law in floridaWeb19 Jul 2024 · Based on data from part 1 of the phase III CASSIOPEIA trial, in September 2024, the FDA granted approval to daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) for adults with newly diagnosed multiple myeloma who are eligible for ASCT. 6,7 An interim analysis from part 2 of the trial … langley rams twitterWebHigh-risk cytogenetic abnormalities and International Staging System (ISS) disease stage III confer poor outcomes in MM pts. In the phase 3 CASSIOPEIA study, at median follow … langley rams rosterWebmyeloma. N Engl J Med. 2024;376(14):1311-1320. 3.Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears … hemp laundry wash bagWeb26 May 2024 · 8003 Background: VTd is a standard of care (SoC) for TE NDMM. CD38 mAb DARA significantly reduced the risk of progression/death and improved CR and MRD … langley raptor cafe menuWeb31 Dec 2015 · The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in Transplant Eligible … hemp law in texas